3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
2
Leukemia, Myeloid, Acute
2
Osteoarthritis
1
Lymphoma, B-Cell
1
Low Back Pain
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Cancer Pain
1
Interventions
Rituximab
82
venetoclax
56
ibrutinib
46
obinutuzumab
43
Bendamustine Hydrochloride
40
idelalisib
30
Cyclophosphamide
29
acalabrutinib
28
fludarabine
27
Chlorambucil
27
pirtobrutinib
18
ublituximab
16
ofatumumab
16
zanubrutinib
14
umbralisib
14
Lenalidomide
11
fludarabine phosphate
9
Alemtuzumab
9
navitoclax
7
duvelisib
7
Azacitidine
5
lumiliximab
4
aflibercept
4
TRU 016
4
Interleukin-2
4
BI 836826
4
ARQ531
4
tafasitamab
3
motexafin gadolinium
3
dinaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
Inosine Monophosphate
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled